Phase II randomized study of maintenance regorafenib vs placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastatic gastric or gastroesophagel junction cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms MANTRA
- 07 Apr 2016 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 19 May 2015 New trial record